Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JY028 in nAMD
NCT03725566Phase 1Unknown
- Sponsor
- Beijing Tongren Hospital
- Start
- May 2018
- Primary completion
- May 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JHL1149 in neovascular age-related macular degeneration (NVAMD), sponsored by Beijing Tongren Hospital. Primary endpoint: Incidence of ocular and systemic adverse events and serious adverse events at 13 weeks. Status: unknown.
02
Drugs
JHL1149
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT03725566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03725566.